The Complete Guide to 3D Bioprinting: Technologies, Bioinks, Applications, and How to Get Started

3D bioprinting is an additive manufacturing process that deposits bioinks — materials containing living cells, growth factors, or biomaterials — layer by layer to fabricate three-dimensional tissue constructs. The two dominant bioprinting modalities are extrusion-based and light-based. Additional techniques serve niche applications. Bioprinting is used in tissue engineering, drug discovery, organ-on-chip development, and regenerative medicine, enabling the creation of physiologically relevant models that outperform traditional 2D cell cultures for research and preclinical testing.

What is 3D bioprinting?

At its simplest, 3D bioprinting is the automated, computer-guided deposition of biological materials to build living structures in three dimensions. Think of it as 3D printing — but instead of plastic or metal, the raw materials include living cells, hydrogels, proteins, and growth factors.

The concept was first articulated in a landmark 2014 review by Murphy and Atala in Nature Biotechnology, which defined 3D bioprinting as the use of additive manufacturing to deposit biocompatible materials, cells, and supporting components into complex 3D functional living tissues. That paper, now cited over 7,000 times, remains the field's foundational reference.

A few years later, a consortium of leading researchers published a more formal consensus definition. In Trends in Biotechnology (2018), Moroni, Boland, Burdick, and colleagues defined biofabrication as the automated generation of biologically functional products with structural organization from living cells, bioactive molecules, biomaterials, cell aggregates, or hybrid cell-material constructs, through bioprinting or bioassembly and subsequent tissue maturation processes.

In practical terms, a bioprinting workflow typically follows four steps:

1. Design — A digital model of the desired construct is created, often from medical imaging (CT/MRI scans) or CAD software.

2. Bioink preparation — Cells are mixed with a carrier material (hydrogel) to form a printable bioink.

3. Printing — The bioprinter deposits the bioink layer by layer according to the digital blueprint, using one of several modalities (extrusion, light-based, or others).

4. Maturation — The printed construct is cultured under controlled conditions, allowing cells to proliferate, migrate, remodel the matrix, and develop functional tissue properties.

The result is a three-dimensional living construct that can serve as a tissue model for drug testing, a building block for regenerative medicine, or a research tool for understanding disease.

How is bioprinting different from regular 3D printing?

The distinction is not just about materials — it is about biology. Regular 3D printing works with inert materials (thermoplastics, resins, metals) at temperatures and pressures that would instantly destroy living cells. Bioprinting must preserve cell viability throughout the entire process, which imposes constraints on every parameter: temperature, pressure, shear stress, crosslinking chemistry, and speed.

This creates what the field calls the biofabrication window — the narrow range of conditions where a material is both printable (stiff enough to hold its shape) and biologically permissive (soft enough for cells to survive, proliferate, and function). The concept was first described by Malda and colleagues in Advanced Materials (2013), who showed that higher polymer concentrations and crosslinking densities improve shape fidelity but create stiff microenvironments that limit cell proliferation, migration, and differentiation.

Seven years later, Levato, Jungst, Groll, Malda, and colleagues revisited the concept in the same journal, documenting how advances — including two-step crosslinking, support bath printing, and coaxial bioprinting — have significantly expanded this window. Today's bioprinting platforms use multi-material capability, temperature control, and tuned crosslinking wavelengths to work within and even widen that window. For example, TissueLabs' TissuePro™ system provides printhead and printbed temperature control from 4°C to 60°C alongside five photocuring wavelengths (365–810 nm), allowing researchers to precisely manage gel-phase transitions and crosslinking dynamics for a broad range of bioinks.

What are the main types of bioprinting technology?

Two primary modalities dominate the field: extrusion-based bioprinting and light-based bioprinting. Each serves distinct purposes, and the choice between them depends on the application, the bioink, and the required resolution and throughput. Additional techniques serve more specialized niches.

Extrusion-based bioprinting

Extrusion is the most widely used bioprinting modality worldwide, and for good reason: it handles the broadest range of bioink viscosities, supports multi-material printing, and is the most versatile platform for tissue engineering research.

In extrusion bioprinting, a bioink is loaded into a syringe or cartridge and pushed through a nozzle to form a continuous filament. The printhead moves in three dimensions (or the stage moves beneath it), depositing the filament layer by layer to build a 3D construct.

The critical engineering question is: how is the bioink pushed through the nozzle? Two principal mechanisms exist, and they differ significantly in precision, reproducibility, and cell viability outcomes.

Pneumatic extrusion

Pneumatic extrusion uses compressed air to push the bioink. It is the simplest and cheapest mechanism and handles a wide viscosity range, which is why it became the default in early commercial bioprinters. However, pneumatic systems carry fundamental limitations that become apparent as soon as reproducibility and cell viability matter.

The core problem is indirect control. The operator sets an air pressure, and the resulting flow rate depends entirely on the bioink's viscosity, temperature, and rheological behavior — all of which can change between batches, over time during a print, or when switching materials. As Zhang and colleagues noted in Nature Reviews Methods Primers (2021), pneumatic systems offer the broadest viscosity range, but exhibit delayed volumetric response — meaning there is a lag between changing the pressure and seeing the flow rate change at the nozzle tip. This lag makes precise deposition difficult and requires iterative manual calibration for every bioink formulation.

Additionally, because the operator is adjusting pressure rather than volume, there is an inherent risk of over-pressurizing to compensate for slow flow, which directly increases shear stress on cells. Blaeser and colleagues demonstrated in Advanced Healthcare Materials (2016) that shear stress must stay below approximately 5 kPa to maintain greater than 90% cell viability, and that both viability and proliferative capacity decrease significantly at higher shear levels. In a pneumatic system, the connection between the pressure setting and the actual shear experienced by cells is indirect and difficult to predict, because it depends on the interplay of air pressure, bioink viscosity, nozzle geometry, and temperature.

Pneumatic systems also require compressed air infrastructure in the lab (air lines, regulators, and filters), which adds setup complexity and limits portability.

Volumetric extrusion (piston-driven / mechanical)

Volumetric extrusion — also called piston-driven or mechanical extrusion — uses a motor-driven plunger to displace the bioink directly. Rather than applying pressure and hoping for the right flow rate, the system controls exactly how much bioink volume is displaced per motor step.

This is a fundamentally superior approach to bioink dispensing. The flow rate is determined by the plunger's physical displacement, not by the bioink's properties — so you get predictable, reproducible deposition without recalibrating when switching bioinks, adjusting concentrations, or printing at different temperatures. The Nature Reviews Methods Primers review by Zhang and colleagues explicitly states that piston-driven systems provide the most precise flow-rate control, independent of bioink properties.

The advantages of volumetric extrusion extend beyond convenience to cell viability. Because the operator controls volume displacement directly rather than air pressure, it is straightforward to set precise flow rates that keep shear within the safe zone — without trial-and-error pressure tuning. Li and colleagues established the quantitative relationship between dispensing pressure, nozzle geometry, and cell damage in Tissue Engineering Part C (2010), showing that cells experience dominant shear stress near nozzle walls that increases with applied pressure and decreases with nozzle diameter. In a volumetric system, the controlled, smooth plunger motion delivers consistent shear profiles that are easier to predict and optimize.

Volumetric systems also eliminate the need for compressed air lines entirely — reducing lab infrastructure requirements and making the system more portable and self-contained.

This is the mechanism used in TissueLabs' TissueStart™ and TissuePro™ bioprinters, with a volumetric precision of 0.1 µL per step. The result is that researchers can focus on biology rather than spending hours calibrating air pressure for every new bioink formulation.

The evidence consistently points toward volumetric (piston-driven) extrusion as the superior mechanism for research bioprinting:

• Direct volume control eliminates pressure-dependent calibration and batch-to-batch variability.

• Predictable shear profiles enable better cell viability outcomes across bioink formulations.

• No compressed-air infrastructure simplifies lab setup and enables the placement of benchtops and biosafety cabinets.

• Reproducibility — a 2024 multi-laboratory round robin study (the first of its kind) found significant operator-dependent variability in extrusion-based printing, attributable to a lack of automation and missing standardization. Volumetric systems reduce this variability because deposition is governed by motor step (a fixed, reproducible parameter) rather than by air pressure (which interacts unpredictably with bioink properties).

A note on screw-driven extrusion: A third mechanism, screw-driven extrusion, uses a rotating screw to push bioink forward. It handles extremely viscous materials but at a high biological cost. Ning and colleagues published the first direct comparative study in Biofabrication (2020), finding that screw-driven bioprinting induces significantly higher cell damage than either pneumatic or piston-driven methods, attributed to additional shear and compressive forces from screw rotation. For most bioprinting applications involving living cells, screw-driven extrusion is not recommended.

Light-based bioprinting

Light-based bioprinting uses photopolymerization — curing a liquid photosensitive bioink (called a bioresin) with light — to build structures with resolution far beyond that of extrusion. Where extrusion excels in material versatility and construct volume, light-based methods excel in speed and precision.

Two technologies dominate light-based bioprinting today: Digital Light Processing (DLP) and Masked Stereolithography (MSLA). Both cure an entire layer at once — making fabrication time dependent on construct height rather than layer complexity — but they differ fundamentally in how they pattern the light.

Digital Light Processing (DLP)

DLP works by projecting a patterned image onto the bioresin surface through a digital micromirror device (DMD) — an array of hundreds of thousands of individually tilting micro-mirrors that selectively reflect light from a projection lamp in the shape of each layer's cross-section. Because the entire layer is cured in a single exposure, a simple disc and a complex vascular network of the same height take the same time to print — a transformative speed advantage over older point-scanning stereolithography methods.

DLP has proven its value for bioprinting applications that demand high resolution. Li and colleagues reviewed DLP for tissue fabrication in iScience (2023), highlighting its ability to replicate sophisticated tissue microenvironments that extrusion cannot achieve. Bhusal and colleagues in ACS Biomaterials Science & Engineering (2022) reported fabrication of vascular channels using DLP-based projection, underscoring its precision for organ-on-chip and microfluidic applications. DLP has been used to fabricate complex scaffold geometries with controlled porosity, microfluidic channel networks for organ-on-chip devices, vascularized tissue constructs with perfusable internal channels, and high-resolution bone and cartilage scaffolds with defined microarchitecture.

The DLP optical architecture consists of a high-intensity light source (mercury arc lamp or single-wavelength LED projector module), condensing optics, the DMD chip, projection lenses, and sometimes UV-filtering optics. Resolution is determined by the DMD's mirror count divided by the projected image area, with most research-grade systems achieving 35–50 µm per pixel. The light source is typically fixed to a single wavelength (365 nm or 405 nm), determined by the lamp spectrum and any optical filters in the projection path. Mercury arc lamps — still common in research-grade systems — are rated for approximately 500–2,000 hours before significant intensity loss and eventual burnout, after which replacement requires realignment and exposure recalibration. The multi-element optical chain generates substantial heat that must be managed through active cooling, and the projection geometry inherently produces brighter illumination at the center of the field than at the edges (vignetting), which can cause differential crosslinking across a single layer. DLP system costs reflect the precision optical components and the complexity of the projection path, placing the technology primarily in well-funded core facilities and established research groups.

Masked Stereolithography (MSLA)

MSLA takes a fundamentally different approach to light patterning. Instead of projecting light through a complex optical chain onto a micromirror array, MSLA positions an LED array directly behind a high-resolution LCD panel. The LCD selectively blocks or transmits light pixel by pixel, curing the bioresin in the desired pattern across the entire build area simultaneously — achieving the same whole-layer curing speed as DLP through radically simpler hardware.

Modern LCD panels achieve pixel sizes as small as 35 µm — matching or exceeding most research-grade DLP systems — at a fraction of the cost, because LCD manufacturing benefits from the massive scale of consumer electronics. The LED light source is equally important. LED arrays maintain stable output over 20,000–50,000 hours with negligible spectral drift, degrade gradually rather than burning out catastrophically, and require no realignment when replaced. Because MSLA uses discrete LED arrays, it is straightforward to integrate multiple wavelengths into the same system — allowing users to select the optimal crosslinking wavelength for each photoinitiator without changing hardware (Irgacure 2959 at 365 nm, LAP at 405 nm, eosin Y at 530 nm, camphorquinone at 470 nm). The direct-backlight geometry provides more spatially uniform illumination than projection-based systems, reducing intra-layer crosslinking variability. And because LEDs generate far less waste heat than projection lamps, MSLA systems need less active cooling — reducing mechanical complexity and radiative heating of the bioresin during printing.

MSLA inherits DLP's speed advantage — whole-layer curing — while resolving its core limitations in cost, optical complexity, light source durability, wavelength flexibility, and illumination uniformity.

TissueLabs' TissueRay™ system uses MSLA technology with 35 µm pixel resolution and three LED wavelengths (405, 450, and 530 nm), making it well-suited for microfluidic devices, organ-on-chip models, and scaffold architectures that require micron-level precision. The multi-wavelength capability is particularly important: different photoinitiators absorb at different wavelengths, and having 405, 450, and 530 nm options means researchers can choose the crosslinking chemistry that best suits their bioresin and cell type — including visible-light photoinitiators that minimize UV-related cell damage.

A note on volumetric bioprinting: An emerging light-based approach, volumetric bioprinting, abandons the layer-by-layer paradigm entirely. Computed-tomography-inspired light projections from multiple angles into a rotating cell-laden bioresin build the entire construct simultaneously — in seconds rather than minutes or hours. However, volumetric bioprinting requires specialized bioresins with carefully tuned optical properties (the resin must be partially transparent at defined depths), construct size is limited by the resin's optical window, multi-material capability is not yet practical, and commercial systems remain scarce.

Other bioprinting techniques

Beyond extrusion and light-based methods, several additional techniques serve specialized niches or represent emerging frontiers. None currently rivals extrusion or MSLA in versatility or commercial adoption, but each addresses specific limitations of the dominant modalities.

Droplet-based bioprinting (inkjet and laser-assisted) encompasses two nozzle-based techniques that deposit bioink as discrete droplets rather than continuous filaments. Inkjet bioprinting uses thermal or piezoelectric actuators to eject tiny droplets (1–100 picoliters) onto a substrate, offering high speed, low cost, and approximately 20 µm placement resolution — but only with very low-viscosity bioinks (below 10 mPa·s) and low cell densities, which severely limits structural complexity. Laser-Induced Forward Transfer (LIFT) uses a pulsed laser to propel bioink droplets from a donor ribbon onto a receiving substrate, achieving micron-level precision and handling cell concentrations up to 10⁸ cells/mL with viability above 95% — but at high equipment cost, low throughput, and with each hydrogel-cell combination requiring specific laser parameter optimization. Both techniques excel at high-resolution patterning of thin layers and precise cell placement, but neither produces the volumetric, structurally robust 3D constructs that tissue engineering typically demands. They are most useful as complementary tools — for example, inkjet-depositing growth factors onto an extrusion-printed scaffold, or LIFT-patterning specific cell populations onto a pre-fabricated construct — rather than as standalone tissue fabrication platforms.

Acoustic / sound-based bioprinting uses ultrasonic waves or surface acoustic waves to manipulate, pattern, and deposit cells and bioink droplets without any physical nozzle contact. The acoustic energy can levitate cells into predefined patterns within a hydrogel (acoustic holographic patterning), eject droplets from an open reservoir (acoustic droplet ejection), or assemble cells into 3D arrangements within seconds using standing wave fields. The key advantage is that acoustic methods are extremely gentle on cells — there is no nozzle passage, no shear stress, and no mechanical contact — consistently yielding viability above 95%. The technology is particularly promising for patterning cells within pre-existing hydrogels (creating organized multicellular architectures without printing the scaffold itself) and for handling fragile cell types like neurons and iPSC-derived cardiomyocytes that are sensitive to mechanical stress. Current limitations include low throughput, limited construct size, difficulty building thick 3D structures (most demonstrations are quasi-2D patterns within thin hydrogel layers), and the early-stage commercial availability of dedicated acoustic bioprinting platforms.

Aspiration-assisted bioprinting (spheroid bioprinting) uses gentle vacuum aspiration to pick up individual pre-formed cell spheroids, organoids, or tissue microgels and place them in precise spatial arrangements. Unlike traditional extrusion — which deposits continuous filaments of cell-laden hydrogel — aspiration-assisted systems handle discrete, pre-matured biological building blocks that already possess internal cellular organization, established cell-cell junctions, and secreted ECM. The spheroids are aspirated one at a time onto a micropipette tip using negative pressure, transported to the target location, and released. After placement, adjacent spheroids fuse via biological self-assembly, gradually forming a continuous tissue. This approach is particularly relevant for fabricating tissues from iPSC-derived organoids (which develop complex internal architecture during culture that would be destroyed by extrusion through a nozzle), for building vascular structures from endothelial spheroids that self-organize into lumens after fusion, and for assembling multi-tissue interfaces where distinct organoid types are placed in defined spatial relationships. The main limitations are speed (single-spheroid placement is inherently slow), scalability (building centimeter-scale constructs from hundreds or thousands of individually placed spheroids is time-consuming), and the requirement for highly standardized spheroid production to ensure consistent size and biological quality.

Which technology should you use?

The choice of bioprinting technology is best understood as a sequence of decisions :

Step 1: Choose your modality — extrusion or light-based?

This is the foundational choice, and it depends primarily on what you are building and the resolution you need.

	Extrusion	Light-based
Resolution	100–500 µm	10–50 µm
Speed	Moderate	Fast (whole layer)
Bioink viscosity range	Broad (most hydrogels)	Moderate (must be photocurable)
Multi-material capability	Yes (multiple printheads, inline mixing)	Limited
Construct size	Medium to large	Small to medium
Best for	Tissue constructs, multi-material architectures, gradient tissues, large-volume scaffolds	Microfluidics, organ-on-chip, vascular networks, precision scaffolds

Choose extrusion when your work involves tissue constructs, multi-material printing, coaxial/triaxial structures, or anything requiring the broadest possible bioink compatibility.

Choose light-based when your work demands micron-level features — microfluidic channels, thin barrier membranes, organ-on-chip devices, or complex scaffold microarchitectures.

Many labs need both — which is why TissueLabs offers extrusion (TissueStart™, TissuePro™) and MSLA (TissueRay™) as complementary platforms.

Step 2 (if extrusion): Volumetric or pneumatic?

	Volumetric (piston-driven)	Pneumatic
Flow control	Direct volume displacement (0.1 µL steps)	Indirect (pressure-dependent)
Calibration	Minimal — motor step is fixed	Manual per bioink, per batch
Cell viability	85–95% (predictable shear)	80–90% (pressure-dependent shear)
Reproducibility	High (motor-controlled)	Lower (operator-dependent)
Compressed air needed	No	Yes
Best for	Most applications — especially when reproducibility and cell viability matter	Legacy setups, extremely high-viscosity pastes

Volumetric extrusion is the best choice for most labs. It eliminates pressure calibration, delivers more predictable cell viability, requires no air infrastructure, and produces more reproducible results across operators and sessions. TissueLabs' TissueStart™ and TissuePro™ both use volumetric piston-driven extrusion.

Step 2 (if light-based): MSLA or DLP?

	MSLA	DLP
Resolution	35–50 µm	35–50 µm
Optical complexity	Minimal (LED array + LCD panel)	High (lamp + DMD + projection optics)
Light source lifespan	20,000–50,000 hours (LED)	500–10,000 hours (lamp/LED projector)
Wavelength flexibility	Multi-wavelength in one system	Single wavelength (filter-dependent)
Illumination uniformity	High (direct backlight)	Center-weighted (projection vignetting)
Maintenance	Low (no alignment, plug-and-play LED replacement)	Higher (optical realignment after lamp replacement)
Heat generation	Low	High (requires active cooling)
System cost	Lower	Higher
Best for	Most light-based applications — microfluidics, organ-on-chip, multi-photoinitiator workflows	Established protocols in well-equipped optical labs

MSLA is the better choice for most labs. It matches DLP resolution while offering superior light source stability, multi-wavelength flexibility, more uniform illumination, and lower cost and maintenance burden. TissueLabs' TissueRay™ uses MSLA with 35 µm pixel resolution and three wavelengths (405, 450, 530 nm).

What are bioinks?

A bioink is a material formulation that contains living cells and is designed to be processed by a bioprinting technology. This definition was formalized by Groll, Burdick, Malda, and colleagues in Biofabrication (2019), who proposed the consensus distinction: bioinks contain living cells as an intrinsic component, while biomaterial inks are cell-free materials that may be seeded with cells after printing.

In practice, most bioinks are hydrogels — water-swollen polymer networks that mimic the soft, hydrated environment of native tissues. Gungor-Ozkerim and colleagues published the most comprehensive bioink overview in Biomaterials Science (2018), cataloging materials across natural and synthetic origins.

The choice of hydrogel determines mechanical properties, cell behavior, crosslinking method, degradation rate, and ultimately whether the printed construct will function as intended. To understand the landscape, it helps to group bioinks into three categories based on their material origin — and to recognize that they differ not just in practical handling but in how closely they can replicate native biology.

1) Protein-based bioinks — the most biomimetic option

Protein-based hydrogels are derived from the structural and signaling proteins found in native tissues. Because they retain natural cell-binding motifs and enzymatic degradation sites, they offer the highest baseline biological relevance among standard bioink materials.

GelMA (Gelatin Methacryloyl) — GelMA is derived from gelatin (denatured collagen) and retains the natural cell-binding RGD motifs and MMP-responsive peptides that make collagen biologically active, while adding photocrosslinkable methacryloyl groups for tunable mechanical properties. It is typically used at 5–15% w/v and crosslinked with a photoinitiator (LAP or Irgacure 2959) under UV or visible light (365–405 nm). GelMA works well in both extrusion and light-based bioprinting, making it one of the most versatile protein bioinks available. The seminal review by Yue and Khademhosseini in Biomaterials (2015) documented its unique combination of biological functionality and processing flexibility. Its main limitations are batch-to-batch variability in degree of methacrylation and the need for careful temperature management during printing, as it transitions between liquid and gel states around 20–25°C. GelMA is the standard choice for labs that need photocrosslinkable biological hydrogels with well-established published protocols.

Collagen (Type I) — Type I collagen is the most abundant protein in the human body and the primary structural component of most extracellular matrices. Collagen bioinks offer excellent biocompatibility and natural cell adhesion through integrin-binding sequences, providing a biologically rich environment without chemical modification. It crosslinks thermally — gelling slowly at 37°C over approximately 30 minutes — or through chemical crosslinkers such as genipin or EDC/NHS. This slow gelation is collagen's primary limitation for bioprinting: the material remains liquid during deposition and takes too long to stabilize, resulting in poor shape fidelity unless strategies such as pH adjustment, rheology modifiers, or blending with faster-gelling materials are employed. Collagen is best suited for applications where native cell-matrix interactions are essential and where constructs can be printed into support baths or molds that maintain shape during the gelation period.

Fibrin — Fibrin is formed by the enzymatic reaction between fibrinogen and thrombin, mimicking the natural wound healing and clot formation matrix. It offers rapid enzymatic crosslinking (gelation in seconds to minutes depending on thrombin concentration), excellent cell adhesion, and high biocompatibility — cells naturally interact with fibrin through integrin receptors just as they do during wound repair in vivo. The main limitations are mechanical weakness (fibrin gels are among the softest protein hydrogels) and rapid degradation by cell-secreted plasmin, which can cause constructs to lose structural integrity within days of printing. For these reasons, fibrin is almost always blended with other materials — collagen, alginate, GelMA, or synthetic polymers — to achieve the structural stability required for bioprinting. Fibrin-based bioinks are most commonly used in vascular tissue engineering, wound healing studies, and applications that benefit from its natural role in angiogenesis and tissue repair.

Silk fibroin — Silk fibroin is a natural protein extracted from Bombyx mori (silkworm) cocoons, valued for its exceptional mechanical strength relative to other protein hydrogels, its slow and tunable degradation rate (weeks to months depending on crystallinity), and its low immunogenicity. It can be crosslinked through multiple mechanisms — enzymatic (tyrosinase or horseradish peroxidase), physical (beta-sheet formation induced by sonication, shear, or methanol treatment), and photochemical (methacrylated silk, or SilMA) — making it compatible with both extrusion and light-based bioprinting. The main limitation is processing complexity: transforming raw silk into a printable bioink requires a multi-step extraction and dissolution workflow that is significantly more involved than preparing GelMA or alginate. Silk fibroin is particularly well suited for applications requiring long-term structural stability — such as bone and cartilage scaffolds — where faster-degrading protein bioinks lose mechanical integrity before new tissue has formed.

Elastin — Elastin is the protein responsible for tissue elasticity in skin, blood vessels, lungs, and ligaments. In its soluble form (tropoelastin) or as recombinantly produced elastin-like polypeptides (ELPs), it provides bioinks with unique elastic and thermoresponsive properties. ELPs exhibit lower critical solution temperature (LCST) behavior — they are soluble below a transition temperature and aggregate above it — enabling temperature-triggered gelation useful for extrusion bioprinting. The primary limitation is that pure elastin hydrogels are mechanically weak and difficult to print with high shape fidelity, so they are most often blended with collagen, GelMA, or other structural proteins to achieve the stiffness needed for printability while retaining elastic behavior. Elastin-based bioinks are most relevant for engineering tissues that must withstand cyclic mechanical loading — vascular grafts, cardiac patches, lung tissue models, and skin constructs where recapitulating native elasticity is a functional requirement.

Decellularized ECM (dECM) bioinks — dECM bioinks are prepared by removing all cellular content from native tissues while preserving the full biochemical complexity of the extracellular matrix — collagens, glycoproteins, growth factors, and glycosaminoglycans in their native, tissue-specific proportions. This makes dECM the closest achievable approximation to the real tissue microenvironment, surpassing any single-protein or synthetic bioink in biological relevance. dECM hydrogels typically crosslink thermally (similar to collagen) and can be further stabilized through photocrosslinking when blended with photoinitiators or methacrylated components. The main historical limitations have been preparation complexity (in-house decellularization requires weeks of optimization per tissue type) and limited commercial availability — most labs had to produce their own dECM from scratch, with no guarantee of batch consistency. TissueLabs is currently the only company in the world offering commercially available tissue-specific dECM hydrogels across 15 distinct tissue types — adipose, bone, brain, cartilage, colon, kidney, liver, lung, muscle, myocardium, pancreas, skin, spleen, stomach, and vascular tissue — under the MatriXpec™ brand. dECM bioinks are covered in detail below as the gold standard for tissue-specific bioprinting — and represent the direction toward which the entire field is converging.

Protein-based bioinks are the preferred choice whenever biological relevance and cell function are the priority. Their main trade-off is handling complexity: they tend to be more temperature-sensitive, more variable between batches, and more technically demanding to print than simpler polysaccharide-based alternatives.

2) Polysaccharide-based bioinks — easier to handle, less biomimetic

Polysaccharide bioinks are derived from sugar-chain polymers. They are generally easier to work with, more consistent between batches, and offer simpler crosslinking mechanisms — making them popular for protocol development, teaching, and applications where printability matters more than biological fidelity.

Alginate — Alginate is a polysaccharide extracted from brown seaweed and the single most widely used bioink in published bioprinting literature. Its defining feature is rapid ionic crosslinking: adding calcium chloride (CaCl₂) solution instantly gels the alginate, enabling fast and reliable post-print stabilization. Alginate is inexpensive, biocompatible, consistent between batches, and forgiving to print across a wide range of concentrations and conditions. However, alginate alone lacks cell adhesion motifs — meaning cells cannot naturally attach to the material — and it degrades unpredictably in culture. Gonzalez-Fernandez and colleagues in Tissue Engineering Part A (2021) confirmed that while alginate provides excellent printability, functional cell engagement requires blending with adhesion-promoting components such as RGD-modified peptides or collagen. Alginate is the standard starting bioink for learning new bioprinting systems and developing printing protocols before moving to more biologically complex materials.

Hyaluronic acid (HA) — Hyaluronic acid is a glycosaminoglycan naturally found in cartilage, skin, and synovial fluid, where it participates in cell signaling, wound healing, and tissue hydration. Native HA has poor mechanical properties and degrades rapidly in culture, but methacrylated HA (MeHA) can be photocrosslinked under UV or visible light, similar to GelMA, making it compatible with both extrusion and light-based bioprinting workflows. Antich and colleagues in Acta Biomaterialia (2020) demonstrated that blending HA with alginate significantly improved both printability and chondrogenic outcomes for cartilage tissue engineering. HA is most commonly used as a co-component or modifier in composite bioinks — adding biological signaling and hydration properties to formulations built around alginate, GelMA, or collagen — rather than as a standalone bioink. It is particularly relevant for cartilage, skin, and neural tissue applications where HA plays a native physiological role.

Cellulose and nanocellulose — Cellulose is the most abundant natural polymer on Earth, and its nanoscale derivatives — cellulose nanofibrils (CNF) and cellulose nanocrystals (CNC) — provide outstanding rheological properties for extrusion bioprinting. Nanocellulose exhibits excellent shear-thinning behavior (the bioink flows under pressure but holds its shape immediately after deposition) and high structural fidelity at very low concentrations (typically 1–3% w/v), making it one of the best available thickening and shape-retention additives. However, cellulose is not biodegradable in the human body (mammals lack cellulase enzymes), which limits its use in implantable constructs, and it provides no cell-adhesion motifs. For these reasons, nanocellulose is most often used as a structural co-component — blended with alginate, GelMA, or other bioactive materials that provide the biological cues while nanocellulose provides the printability. It is particularly effective for cartilage engineering, where its mechanical stiffness and water-retention capacity complement the tissue's requirements.

Chitosan — Chitosan is derived from chitin, the structural polysaccharide of crustacean shells and insect exoskeletons. It is positively charged at physiological pH — an unusual property among natural polymers — which gives it inherent antimicrobial activity and the ability to form electrostatic complexes with negatively charged molecules like DNA, growth factors, and other polysaccharides. Chitosan gels through pH-dependent physical crosslinking (transitioning from solution to gel as pH rises above ~6.5) or through chemical crosslinking with agents such as genipin. Its main limitations for bioprinting are slow gelation kinetics and poor shape fidelity when printed alone, requiring blending with faster-gelling materials like alginate or GelMA to achieve printable rheology. Chitosan-based bioinks are most commonly explored for wound healing (leveraging antimicrobial properties), bone tissue engineering (where it promotes osteogenic differentiation), and drug delivery scaffolds where controlled release of charged therapeutic molecules is desired.

Polysaccharide-based bioinks are excellent for learning bioprinting, developing printing protocols, and applications where structural properties matter more than tissue-specific biology. For tissue engineering applications where cell behavior and differentiation are critical, they typically need to be supplemented with protein-based components or growth factors.

3) Other bioink approaches

Beyond protein and polysaccharide hydrogels, several alternative strategies are used for specialized applications.

Self-assembling peptides (SAPs) — Self-assembling peptides are short synthetic amino acid sequences (typically 8–20 residues) designed to spontaneously organize into nanofibrous hydrogel networks under physiological conditions. Their fiber diameters (approximately 10–20 nm) closely mimic the nanostructure of native ECM — a significant advantage over bulk hydrogels like alginate or PEG that lack this nanoscale architecture. SAPs can be engineered with specific bioactive motifs (RGD for cell adhesion, MMP-cleavable sites for remodeling, growth-factor-binding domains), making them a modular, "designer" platform. The main limitations are practical: most SAP hydrogels are mechanically soft and difficult to extrude with high shape fidelity, and they are significantly more expensive than natural polymer bioinks. SAPs are best suited for niche applications requiring precisely defined matrices — stem cell differentiation studies, mechanotransduction research — rather than large-volume tissue fabrication.

DNA-based bioinks — DNA hydrogels are formed by engineering DNA strands that hybridize into branched, crosslinked networks with extraordinary programmability — stiffness, degradation rate, and bioactive functionality can all be tuned at the sequence level. They are inherently biocompatible, can be designed to degrade on demand (using DNase or toehold-mediated strand displacement), and can incorporate functional sequences such as aptamers for growth factor capture or CpG motifs for immune stimulation. These properties make DNA bioinks conceptually powerful for immunoengineering, smart drug delivery scaffolds, and programmable tissue models. However, DNA-based bioinks remain in the proof-of-concept stage: they are expensive to synthesize at scale, mechanically weaker than most protein or polysaccharide hydrogels, and the bioprinting parameter space is not yet well characterized. They represent an emerging frontier worth watching but are not yet practical for routine tissue engineering.

Cell spheroid and aggregate bioinks — Rather than suspending individual cells in a hydrogel carrier, these approaches use pre-formed cellular aggregates — spheroids, organoids, or tissue strands — as building blocks that are printed and allowed to fuse during maturation. This strategy bypasses the bioink scaffold entirely, relying on cell-cell adhesion and self-organization to generate tissue structure. The biological outcomes can be impressive (spheroid fusion recapitulates aspects of embryonic development), but the approach is technically challenging: achieving precise spatial placement of fragile aggregates requires specialized dispensing systems, and the constructs lack immediate mechanical integrity. Spheroid-based bioprinting is most relevant for vascular tissue engineering (using tissue strands as building blocks) and organoid-based disease modeling.

Composite and hybrid bioinks — Many practical bioink formulations blend materials from multiple categories to balance biological function with printability. Common combinations include GelMA + alginate (photocrosslinking + ionic stabilization), collagen + HA (cell adhesion + signaling), dECM + GelMA (tissue specificity + mechanical tunability), and nanocellulose + alginate (structural fidelity + biocompatibility). Composite approaches are increasingly the norm rather than the exception in published bioprinting protocols, reflecting the reality that no single material simultaneously optimizes for printability, cell viability, biological function, and mechanical properties. The trend toward composites also reinforces the importance of multi-material bioprinting platforms that can handle different formulations in the same print — either through multiple printheads or through inline mixing systems like TissueLabs' Mixtrusor™.

The gold standard: tissue-specific dECM bioinks

If the goal of bioprinting is to create tissue constructs that behave like real tissues, the logical question becomes: what material most closely replicates the native tissue microenvironment? The answer is decellularized extracellular matrix (dECM) — and specifically, tissue-matched dECM hydrogels.

The native ECM is the complex three-dimensional scaffold that surrounds cells in every tissue of the body. It is not a passive structural support — it is an active signaling network of collagens, glycoproteins, proteoglycans, growth factors, and matrix-bound vesicles that directs cell adhesion, migration, proliferation, differentiation, and function. Every tissue has a unique ECM composition: liver ECM differs from cardiac ECM, which differs from brain ECM, which differs from cartilage ECM. These differences are not trivial — they fundamentally shape how cells behave.

Decellularization removes the cells from a tissue while preserving this complex matrix. The resulting dECM retains the native proportions of tissue-specific proteins and signaling molecules that no synthetic hydrogel, generic protein-based bioink, or polysaccharide can replicate. The practical implication is clear: if you are modeling liver drug metabolism, your cells should be in a liver-specific ECM. If you are studying cardiac toxicity, cardiac-specific matrix cues matter. If you are engineering cartilage, cartilage-derived ECM guides chondrogenic differentiation more effectively than alginate or GelMA alone.

TissueLabs' MatriXpec™ line was developed around this principle. MatriXpec hydrogels are decellularized ECM-based biomaterials available for 15 distinct tissue types — adipose, bone, brain, cartilage, colon, kidney, liver, lung, muscle, myocardium, pancreas, skin, spleen, stomach, and vascular tissue. No other commercially available line spans this breadth of tissue-specific formulations, making MatriXpec™ particularly relevant for labs working across multiple tissue engineering applications or requiring tissue-matched microenvironments for disease modeling, drug screening, and regenerative medicine research.

How do you choose a bioink?

The right bioink depends on your workflow preferences, your crosslinking equipment, and how much biological relevance your application demands. Most researchers start with a conventional bioink they already know — and the question becomes whether to stay there or upgrade to a tissue-specific alternative that uses the same crosslinking chemistry.

1. If you prefer thermal gelation → collagen or MatriXpec™ Thermo. Thermal gelation is the gentlest crosslinking method: the bioink is liquid when cold and gels gradually when warmed to 37°C, requiring no chemicals, no light exposure, and no specialized equipment beyond temperature control. Collagen is the conventional choice here — it provides natural cell adhesion and is biologically well characterized, but it is a single purified protein that lacks the full spectrum of growth factors, glycoproteins, and tissue-specific signaling molecules present in native ECM. Its slow gelation (~30 minutes) also limits shape fidelity after printing. MatriXpec™ Thermo uses the same thermal crosslinking workflow but replaces a single protein with the complete biochemical complexity of tissue-matched decellularized ECM — preserving the native proportions of collagens, GAGs, growth factors, and matrix-bound signals specific to each of 15 tissue types. For labs already comfortable with collagen handling, MatriXpec Thermo is the natural upgrade: same crosslinking principle, same temperature-controlled workflow, but dramatically richer biological content.

2. If you prefer photocrosslinking → GelMA or MatriXpec™ Photo. Photocrosslinking offers the best combination of speed (seconds under light), mechanical tunability (adjustable via light dose and photoinitiator concentration), and structural fidelity (immediate stabilization prevents filament spreading). GelMA is the established standard — photocrosslinkable, biologically active (retains RGD and MMP-responsive motifs from gelatin), and compatible with both extrusion and light-based bioprinting. But GelMA is a generic gelatin derivative: it provides the same non-specific biological background regardless of whether you are printing liver, brain, or cartilage. MatriXpec™ Photo offers the same UV/visible light crosslinking convenience — same photoinitiators, same exposure workflows, same compatibility with extrusion and MSLA systems — while replacing that generic gelatin background with tissue-specific dECM. For labs already running GelMA protocols, switching to MatriXpec Photo requires minimal workflow changes but delivers a fundamentally different biological environment: one where cells receive the tissue-matched signals that drive physiologically relevant behavior, not just a permissive scaffold.

3. If you prefer ionic crosslinking → alginate or MatriXpec™ Ionic. Ionic crosslinking with CaCl₂ is the simplest and most forgiving method in bioprinting: spray, bathe, or co-print the crosslinker, and the bioink gels in seconds. Alginate built its dominance on this simplicity — it is cheap, consistent, and nearly impossible to fail with. But alginate is biologically inert: no cell adhesion motifs, no signaling molecules, no tissue-specific cues. Cells in alginate are alive but not receiving the matrix instructions that drive differentiation, function, or physiologically relevant drug responses. MatriXpec™ Ionic uses the exact same CaCl₂ crosslinking workflow — the handling feels identical to alginate — but replaces the inert polysaccharide with tissue-specific decellularized ECM. For labs that have built their entire bioprinting pipeline around alginate, MatriXpec Ionic is the lowest-friction upgrade path to biological relevance: same crosslinker, same timing, same workflow, completely different biology.

In every case, the pattern is the same: the conventional bioink established the crosslinking workflow, and the corresponding MatriXpec formulation preserves that workflow while replacing a generic or single-component material with the full biochemical complexity of tissue-matched native ECM. Labs do not need to choose between processing convenience and biological relevance — MatriXpec Thermo, Photo, and Ionic make both available simultaneously for all 15 tissue types.

Choosing between MatriXpec™ Thermo, Photo, and Ionic

For labs that have decided on tissue-specific dECM as their bioink — or that want to upgrade from generic hydrogels to tissue-matched biomaterials — the next question is which MatriXpec crosslinking format best fits their workflow, equipment, and application. All three formulations share the same tissue-specific dECM foundation (the same decellularized matrix, preserving the same native proteins, growth factors, and GAGs), so the biological content is equivalent. The difference is how the hydrogel is stabilized after printing or casting.

	MatriXpec™ Thermo	MatriXpec™ Photo	MatriXpec™ Ionic
Crosslinking mechanism	Thermal gelation at 37°C	Photopolymerization (UV/visible light + photoinitiator)	Ionic crosslinking (CaCl₂ solution)
Gelation speed	Gradual (minutes)	Rapid (seconds under light exposure)	Rapid (seconds upon CaCl₂ contact)
Mechanical tunability	Limited (gelation conditions fixed)	High (adjustable via light dose, photoinitiator concentration, exposure time)	Moderate (adjustable via CaCl₂ concentration and exposure time)
Equipment requirements	Temperature-controlled printhead and/or printbed	Light source at compatible wavelength + photoinitiator	CaCl₂ solution (sprayed, bathed, or co-printed)
Shape fidelity after printing	Lower (slow gelation allows some spreading)	High (immediate stabilization under light)	High (immediate stabilization on CaCl₂ contact)
Bioprinting compatibility	Extrusion (best with temperature control)	Extrusion + light-based (MSLA, DLP)	Extrusion
Closest conventional equivalent	Collagen	GelMA	Alginate
Best for	3D cell culture, manual casting, gentle encapsulation where mechanical demands are low	Bioprinting workflows requiring precise shape fidelity and tunable stiffness; MSLA/DLP bioresin applications	Fast-stabilization extrusion workflows; labs transitioning from alginate who want biological relevance without changing their crosslinking protocol

In practice, many labs use more than one formulation depending on the application. A single lab might use MatriXpec Thermo for 3D cell culture screening experiments, MatriXpec Photo for bioprinted tissue models requiring defined stiffness and structural precision, and MatriXpec Ionic for rapid extrusion prototyping of new construct geometries — all using the same tissue-specific dECM base, ensuring biological consistency across experimental formats.

What can you do with bioprinting? Key applications

New Approach Methodologies (NAMs) for drug development

The drug development industry is broken — and bioprinting is emerging as one of the most credible paths to fixing it. It costs an average of $2.6 billion and takes 12–15 years to bring a single drug to market. Over 90% of candidates that enter clinical trials ultimately fail, many because 2D cell cultures and preclinical animal models did not predict human toxicity or efficacy. The core problem is that the preclinical tools the industry has relied on for decades — flat monolayers of cells in plastic dishes and rodent or primate models with fundamentally different biology — are poor proxies for what happens inside a human body.

This is driving a historic shift toward New Approach Methodologies (NAMs) — the umbrella term for non-animal technologies, including 3D bioprinted tissue models, organ-on-chip (OoC) microphysiological systems, computational and AI-driven models, organoids, and advanced in vitro assays. NAMs are not a niche academic concept; they are now embedded in regulatory frameworks worldwide.

The FDA Modernization Act 2.0, signed into law in the United States in December 2022, was the watershed moment. For the first time, it removed the legal requirement that drugs must be tested on animals before entering human clinical trials. The act explicitly recognizes "cell-based assays, microphysiological systems" (the regulatory term for organ-on-chip devices), and "bioprinted or artificial human tissue" as acceptable alternatives to animal studies for demonstrating drug safety and efficacy. This was not a symbolic gesture — the FDA has since established the Alternative Methods Working Group, published guidance documents encouraging sponsors to include microphysiological system data and 3D tissue model results in regulatory submissions, and has already accepted organ-on-chip data in Investigational New Drug (IND) applications.

Europe is moving in parallel. The European Medicines Agency (EMA) has established a dedicated working group on NAMs to evaluate their integration into regulatory pathways. The EU's REACH regulation for chemical safety testing is shifting toward acceptance of advanced in vitro models. The European Commission's commitment to phase out animal testing for cosmetics has already made bioprinted skin models a commercial reality — cosmetics companies routinely use them for dermal absorption and irritation testing in lieu of animal studies. And in 2025, the ICH (International Council for Harmonisation) began developing guidelines for qualifying NAMs as regulatory tools across member regions — a signal that acceptance of bioprinted tissue models in formal drug submissions will expand globally.

For the bioprinting industry, this regulatory convergence is transformative. What was once a research tool is becoming a pharmaceutical platform. The rationale is grounded in basic cell biology: cells behave differently in 3D than in 2D. Gene expression, drug metabolism, receptor signaling, and treatment response all change when cells are embedded in a three-dimensional matrix that mimics their native environment. Hepatocytes in 2D monolayers lose CYP450 enzyme activity within days; the same cells in a 3D bioprinted liver model maintain metabolic function for weeks. Cardiomyocytes in 2D lack the mechanical environment that drives sarcomere maturation; in 3D bioprinted cardiac tissue they develop functional contractile properties. Kidney epithelial cells lose polarization and transporter expression in flat culture; in 3D bioprinted tubule models they maintain the directional secretion that determines nephrotoxicity. For pharma teams, this means more predictive preclinical data and fewer expensive late-stage failures.

Bioprinted NAMs for drug development take several forms, each suited to different stages of the pharmaceutical pipeline:

Bioprinted tissue models are the most straightforward application: 3D constructs of a specific tissue type — liver, cardiac, kidney, skin, brain, tumor — fabricated by bioprinting and used as in vitro test platforms. Companies are already using bioprinted liver models for ADME studies (absorption, distribution, metabolism, excretion), kidney proximal tubule models for nephrotoxicity prediction, cardiac tissue models for proarrhythmic risk assessment (replacing or supplementing the hERG assay), skin models for dermal absorption and irritation testing, and brain tissue models for neurotoxicity screening and blood-brain barrier permeability studies. These models sit in standard well plates and can be scaled to medium-throughput formats compatible with existing pharmaceutical screening infrastructure.

Organ-on-chip (OoC) devices add a layer of physiological complexity by combining bioprinted tissue constructs with microfluidic channels that simulate blood flow, mechanical forces, and inter-organ communication. The result is a miniaturized organ model that recapitulates dynamics that static 3D cultures cannot — shear stress on endothelial walls, cyclic mechanical strain on lung alveoli, peristaltic motion in gut models, and nutrient/waste gradients across tissue barriers. Organ-on-chip devices have moved from academic curiosities to serious pharmaceutical tools: multiple pharma companies now use them in preclinical pipelines, and the FDA has accepted OoC data in IND applications. The key advantage of bioprinted organ-on-chip systems over manually assembled ones is reproducibility and architectural complexity — bioprinting enables precise, automated deposition of multiple cell types in defined spatial arrangements that manual seeding simply cannot match. This application demands high resolution, which is why MSLA-based light bioprinting is the preferred fabrication modality. Microfluidic channels, vascular networks, and tissue barriers all require features in the 10–50 µm range, well below the resolution of extrusion bioprinting. TissueLabs' TissueRay™, with its 35 µm pixel resolution and multi-wavelength LED array (405, 450, and 530 nm), was designed specifically for organ-on-chip and microfluidic device fabrication.

Multi-organ and body-on-chip systems connect multiple organ-on-chip modules — liver, heart, kidney, gut, lung — through shared microfluidic circulation, enabling the study of systemic drug effects, organ-organ interactions, and multi-organ toxicity in a single integrated platform. For example, a drug metabolized by a bioprinted liver module can flow to a cardiac module where its metabolites are tested for cardiotoxicity — replicating the same sequence that occurs in a living patient. These systems represent the most ambitious NAM application and the closest in vitro approximation to whole-body pharmacokinetics.

Across every NAM application, a consistent principle holds: the biomaterial environment shapes the biological readout. A liver drug metabolism model cultured in alginate is not receiving the hepatic matrix signals that drive CYP450 expression. A cardiac safety model built in generic GelMA is missing the myocardial-specific cues that promote functional electromechanical coupling. A kidney nephrotoxicity screen built in collagen alone lacks the tubular basement membrane composition that maintains transporter protein expression and epithelial polarity. As regulatory agencies increasingly scrutinize the physiological relevance of preclinical models — and as the bar for NAM acceptance in regulatory submissions rises — choosing the right microenvironment for cells is becoming a data-quality issue, not just a scientific preference. A drug company submitting organ-on-chip data to the FDA must demonstrate that the model recapitulates the relevant human biology. Tissue-specific biomaterials, like MatriXpec™ hydrogels, are a foundational component of that demonstration.

Personalized medicine and diagnostics

Bioprinting's transformative long-term promise is beyond fabricating generic tissue models — it is fabricating patient-specific ones. The ability to take a patient's own cells, embed them in a tissue-matched biomaterial, print them into a physiologically relevant 3D architecture, and use the resulting construct to guide clinical decisions is no longer theoretical. It is happening today in oncology, advancing rapidly in regenerative medicine, and emerging in rare disease research and diagnostic applications.

Cancer and tumor modeling

Bioprinted tumor models are among the most impactful near-term applications of personalized bioprinting, driven by the growing recognition that traditional cancer research tools fail to capture the complexity of the human tumor microenvironment (TME). 2D cell cultures lack spatial architecture, mechanical cues, and cell-cell interactions. Matrigel-based spheroids self-organize but offer no control over geometry or cell placement. Animal xenograft models suffer from species-specific differences in tumor biology, immune response, and drug metabolism that limit their predictive value for human outcomes — a reality that the NAMs movement and the FDA Modernization Act 2.0 are explicitly designed to address.

What bioprinting adds to cancer research is spatial control over the tumor microenvironment: the ability to place cancer cells within a defined extracellular matrix, surrounded by stromal fibroblasts, immune cells, endothelial cells, and vascular structures in precise, reproducible patterns. This matters because the TME is not passive — it actively shapes drug resistance, immune evasion, metastatic behavior, and treatment response. A breast cancer cell in a 2D dish responds differently to chemotherapy than the same cell embedded in a 3D matrix surrounded by cancer-associated fibroblasts and tumor-recruited macrophages.

The most exciting application is functional precision oncology — printing a patient's own tumor cells into a standardized 3D microenvironment, fabricating dozens of replicate constructs, exposing each replicate to a different drug or combination regimen, and measuring which treatment is most effective before administering it to the patient. This transforms cancer treatment selection from population-level statistical guesswork (based on tumor type and genomic markers) into direct, individualized functional testing. Several academic medical centers and companies are already running clinical feasibility studies using this approach for treatment selection in pancreatic, ovarian, and colorectal cancers — tumor types where first-line response rates are low and the cost of choosing the wrong regimen is measured in months of a patient's life.

Rare disease modeling

Rare diseases collectively affect over 300 million people worldwide, yet the vast majority of the approximately 7,000 known rare diseases have no approved treatment. Drug development for rare diseases is hampered by tiny patient populations (making clinical trials difficult to power statistically), limited availability of disease-relevant animal models (many rare diseases have no natural animal counterpart), and the prohibitive cost of developing drugs for small markets.

Bioprinted tissue models derived from patient-specific iPSCs (induced pluripotent stem cells) offer a path forward. The workflow is: take a skin or blood sample from a rare disease patient, reprogram the cells into iPSCs, differentiate them into the affected cell type (cardiomyocytes for a rare cardiomyopathy, hepatocytes for a rare metabolic liver disease, neurons for a rare neurodegenerative condition), and bioprint them into a 3D tissue model that recapitulates the disease phenotype. The result is a patient-derived, disease-specific model that can be used for drug screening, mechanistic research, and even regulatory submissions as supporting evidence for orphan drug applications.

Bioprinted rare disease models have particular value for genetic cardiomyopathies (where patient-derived iPSC-cardiomyocytes printed into cardiac-matched constructs develop disease-specific contractile and electrophysiological phenotypes), hepatic metabolic disorders (where bioprinted liver models maintain the enzymatic deficiencies characteristic of conditions like Wilson's disease, alpha-1 antitrypsin deficiency, or urea cycle disorders), and neuromuscular diseases (where bioprinted muscle and neuromuscular junction models can capture the functional deficits of conditions like Duchenne muscular dystrophy or spinal muscular atrophy).

Pharmacogenomics-matched tissue models

Pharmacogenomics — the study of how genetic variation affects drug response — has revealed that patients with different genotypes metabolize drugs at dramatically different rates, experience different toxicity profiles, and respond differently to the same treatment. The most well-known example is CYP2D6 polymorphism, which affects the metabolism of approximately 25% of all prescribed drugs: poor metabolizers accumulate toxic levels of drugs that normal metabolizers clear efficiently, while ultra-rapid metabolizers may never reach therapeutic concentrations.

Bioprinting creates the possibility of fabricating tissue models from cells with defined genetic backgrounds — either patient-derived or genotype-selected iPSC lines — and testing drugs on the specific pharmacogenomic variant relevant to a patient population. A bioprinted liver model using hepatocytes from a CYP2D6 poor metabolizer will produce toxicity data directly relevant to that patient subgroup, data that a model built from generic cell lines cannot provide. This approach is still early-stage, but it aligns with the pharmaceutical industry's broader move toward precision medicine and adaptive clinical trial designs that stratify patients by genotype.

Diagnostic and prognostic applications

An emerging frontier is the use of bioprinted tissue constructs not for drug testing but for diagnostic and prognostic purposes — predicting disease progression or treatment outcomes based on how a patient's own cells behave in a controlled 3D environment.

In oncology, this means using bioprinted tumor models not just to select among existing drugs but to predict whether a patient's cancer is likely to metastasize, develop resistance, or respond to immunotherapy — based on observed behavior in a 3D bioprinted model that recapitulates the patient's specific tumor biology and microenvironment. In cardiovascular medicine, bioprinted cardiac tissue from a patient's iPSC-derived cardiomyocytes could serve as a functional diagnostic platform for arrhythmia risk stratification — testing whether a patient's heart cells exhibit the electrophysiological abnormalities that predict sudden cardiac events, before those events occur. In fibrotic diseases (liver fibrosis, pulmonary fibrosis, kidney fibrosis), bioprinted tissue models using patient-derived cells could predict the rate of disease progression and identify which patients will benefit from early aggressive intervention versus conservative management.

These diagnostic applications are conceptually powerful but technically early. They require robust, reproducible bioprinting workflows, well-characterized patient-derived cell sources, and clinical validation studies that correlate in vitro model behavior with actual patient outcomes. The foundation for all of them, however, is the same: a bioprinting platform capable of fabricating physiologically relevant 3D tissue constructs from patient-specific cells in tissue-matched biomaterials — precisely what the combination of TissueLabs' bioprinters and MatriXpec tissue-specific dECM hydrogels is designed to enable.

Tissue engineering for therapeutics

The ultimate promise of bioprinting is to fabricate living tissue constructs that can be implanted into patients to repair, replace, or regenerate damaged organs. The global organ shortage is staggering: over 100,000 patients are on transplant waiting lists in the United States alone, and roughly 17 people die every day waiting for an organ that never arrives. For tissues like cartilage, skin, bone, and muscle — where transplantation is not even an option — chronic injuries and degenerative diseases affect hundreds of millions of people worldwide with limited treatment options beyond pain management or mechanical prosthetics.

Bioprinting offers a path toward patient-specific, on-demand tissue fabrication that could fundamentally change these numbers. While whole-organ bioprinting remains a long-term goal, clinically relevant tissue constructs — patches, grafts, implants, and engineered tissue segments — are advancing through preclinical development toward first-in-human applications. Below is a summary of where the field stands across the most actively pursued tissue types.

Skin — Chronic wounds, burns, and diabetic ulcers represent an enormous unmet clinical need: over 11 million burn injuries require medical attention globally each year, and chronic non-healing wounds affect approximately 2.5% of the population in developed countries. Current treatment relies on autografts (limited by donor site availability), allografts (limited by immune rejection), and synthetic wound dressings (which promote closure but not true regeneration). Bioprinted skin constructs offer a fundamentally different approach — multi-layered grafts that replicate the dermis-epidermis architecture of native skin, with stratified keratinocyte layers, fibroblast-populated dermal matrices, and melanocyte integration. More recent work has advanced toward printing skin appendages — hair follicles, sweat glands, and sebaceous glands — which are critical for functional wound healing but absent from every current graft technology. Vascularized skin models incorporating endothelial cell networks are also progressing rapidly, driven by the clinical reality that thick grafts fail without blood supply. Skin bioprinting benefits from relatively simple geometry and well-characterized cell sources, making it one of the closest applications to clinical translation — and one of the first areas where bioprinted constructs may reach patients.

Cartilage — Osteoarthritis affects over 500 million people worldwide and is the leading cause of disability in adults over 60. The clinical challenge is that articular cartilage has almost no natural regenerative capacity — once damaged, it does not heal. Current surgical options (microfracture, autologous chondrocyte implantation, osteochondral transfer) provide symptomatic relief but do not restore native tissue architecture. Bioprinting aims to fabricate cartilage constructs that recapitulate the zonal organization of native articular cartilage — the superficial, transitional, and deep zones that each have distinct collagen fiber orientations and mechanical properties. The key biological challenge is directing cells toward the correct phenotype: hyaline cartilage (rich in type II collagen and aggrecan, the functional load-bearing cartilage of joints) versus fibrocartilage (rich in type I collagen, mechanically inferior). Daly and Kelly demonstrated in Biofabrication (2016) that bioink choice directly determines which phenotype develops. Reinforcement with polycaprolactone (PCL) frameworks has yielded constructs with compressive moduli approaching native tissue values. Researchers have also bioprinted osteochondral interfaces — gradient constructs that transition from bone at the base to cartilage at the surface — which are critical for joint resurfacing procedures. Cartilage bioprinting is among the closest applications to clinical implantation because cartilage is avascular (eliminating the vascularization bottleneck that limits other tissues) and immunologically privileged.

Bone — Bone defects from trauma, tumor resection, congenital malformations, and non-union fractures affect millions of patients annually. The current gold standard — autologous bone graft — requires a secondary surgical site, is limited in volume, and carries donor site morbidity. Allografts and synthetic bone substitutes lack the biological activity to drive true regeneration in large, critical-size defects. Bioprinting approaches combine cell-laden hydrogels (seeded with osteoblasts or mesenchymal stem cells) with load-bearing PCL or ceramic frameworks in hybrid constructs designed to provide both the biological signals for osteogenesis and the mechanical strength to support the defect during healing. The main clinical challenges are achieving sufficient compressive strength (native cortical bone reaches 100–200 MPa, far beyond any current bioink), incorporating the mineral phase (hydroxyapatite), and vascularizing constructs large enough for clinically relevant defects. Bioprinted bone models are already widely used in vitro for studying osteogenesis and bone-tumor interactions, and several groups are advancing toward preclinical implantation studies in large-animal models.

Cardiac tissue (myocardium) — Heart failure following myocardial infarction is a leading cause of death worldwide. A single heart attack can destroy up to one billion cardiomyocytes, and the adult human heart has virtually no capacity to regenerate lost muscle. Current treatments (medication, ventricular assist devices, transplantation) manage symptoms but do not replace dead tissue. Bioprinted cardiac patches aim to restore contractile function by delivering iPSC-derived cardiomyocytes in a mechanically and biochemically appropriate matrix directly onto the damaged myocardium. Researchers have fabricated beating patches that achieve synchronized contractile function and electromechanical coupling in millimeter-scale constructs. The clinical barriers are formidable: cardiomyocytes are among the most metabolically demanding cells in the body, requiring dense vascular networks, precise cellular alignment for coordinated contraction, and a mechanical environment that matches native myocardial stiffness (~10 kPa). Electrical integration with the host heart — without inducing arrhythmias — remains an unsolved challenge. Despite these hurdles, cardiac bioprinting is advancing toward first-in-human safety trials, with several groups targeting cardiac patch implantation within the next five years.

Liver — Liver disease kills over two million people per year globally, and the organ shortage is acute: only about 25% of waitlisted liver transplant patients receive an organ. The liver is unique in its regenerative capacity — it can regrow from as little as 25% of its original mass — which opens therapeutic strategies beyond whole-organ replacement. Bioprinted hepatic constructs aim to provide functional liver tissue that can either be implanted as a bridge to transplant (maintaining metabolic function while the patient waits) or as a permanent supplement that takes over critical metabolic duties. Researchers have fabricated hepatic lobule-inspired constructs with zonally organized hepatocytes, stellate cells, and endothelial cells that maintain albumin secretion, urea synthesis, and cytochrome P450 enzyme activity for weeks — functions that are rapidly lost in standard 2D hepatocyte cultures. The clinical path forward likely involves implanting bioprinted liver tissue into the omentum or mesentery (rather than the liver itself), where it can access blood supply and perform metabolic functions without requiring the full architectural complexity of a native liver lobule.

Brain and neural tissue — Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS), traumatic brain injury, spinal cord injury, and stroke collectively represent the largest unmet therapeutic need in medicine. The central nervous system has extremely limited regenerative capacity, and no current therapy can replace lost neurons or restore severed neural circuits. Bioprinting neural tissue is among the most challenging therapeutic applications — neural tissue is extremely soft (~0.5–1 kPa), neurons are highly sensitive to mechanical stress during printing, and functional neural architecture requires precise spatial patterning of multiple cell types (neurons, astrocytes, oligodendrocytes) across distinct layers with guided axonal connectivity. A landmark 2024 study by Yan and colleagues in Cell Stem Cell demonstrated the first successful 3D bioprinting of human neural tissues with functional synaptic connectivity — a critical milestone. While implantable neural tissue remains a distant goal, bioprinted neural constructs are already enabling disease-specific modeling for Alzheimer's, Parkinson's, and glioblastoma, accelerating therapeutic discovery for conditions that desperately need new treatments.

Vascular tissue — Cardiovascular disease is the world's leading cause of death, and millions of patients require vascular grafts annually for coronary bypass, peripheral artery disease, and dialysis access. Synthetic grafts (Dacron, ePTFE) work well for large-diameter vessels but fail at small diameters (<6 mm) due to thrombosis and intimal hyperplasia. Bioprinted vascular constructs aim to provide living, cellularized grafts that remodel and integrate with the patient's circulatory system. Researchers have fabricated tubular vascular structures using coaxial extrusion (creating hollow tubes in a single pass), sacrificial ink strategies (printing temporary channels that are dissolved to leave perfusable networks), and direct cell-sheet approaches. Beyond grafts, vascularization is the enabling technology for every other thick tissue construct — without a blood supply, cells in the interior of constructs thicker than approximately 200 µm die from oxygen and nutrient deprivation. Multi-scale vascular networks — from large arteries down to capillary-scale channels — remain the field's grand challenge.

Lung — Chronic respiratory diseases (COPD, pulmonary fibrosis, cystic fibrosis) affect over 500 million people globally, and end-stage lung disease has no treatment other than transplantation — for which donor organs are critically scarce. Bioprinting lung tissue targets the air-blood barrier, the ultrathin interface (~0.5 µm) between alveolar epithelial cells and capillary endothelial cells where gas exchange occurs. Researchers have fabricated alveolar-like structures with thin-walled air sacs surrounded by vascular channels. Replicating the full branching complexity of the human lung (approximately 300 million alveoli with a total surface area of 70 m²) remains far beyond current capabilities, but bioprinted lung tissue segments could serve as implantable gas-exchange modules that supplement — rather than replace — native lung function in patients with progressive respiratory failure.

Kidney — Chronic kidney disease affects approximately 850 million people worldwide, and end-stage renal disease kills over one million annually. Dialysis sustains life but does not replace the kidney's full metabolic and endocrine functions, and transplant waiting lists continue to grow. The kidney's extraordinary structural complexity — each human kidney contains approximately one million nephrons with intricate tubular and vascular architectures — makes it one of the most challenging organs to bioprint. Current therapeutic-oriented work focuses on fabricating bioartificial kidney devices: bioprinted proximal tubule constructs integrated with filtration membranes that could replicate the kidney's reabsorption and secretion functions in an extracorporeal or implantable format. Full kidney fabrication remains a distant goal, but functional nephron-unit-level constructs represent a credible intermediate therapeutic target.

Pancreas — Type 1 diabetes affects over 8 million people globally, and current treatment requires lifelong insulin injection or pump therapy. Islet cell transplantation (the Edmonton Protocol) demonstrates that replacing insulin-producing beta cells can achieve insulin independence, but the approach is limited by donor organ scarcity and the need for immunosuppression. Bioprinting aims to fabricate islet-like constructs that achieve glucose-stimulated insulin secretion while providing immunoprotective encapsulation that shields the cells from immune attack. Researchers have bioprinted beta-cell-laden constructs demonstrating functional insulin secretion, and encapsulated islet models designed with semi-permeable barriers that allow glucose and insulin diffusion while blocking immune cells and antibodies. The pancreas presents unique challenges: islet cells are extremely sensitive to hypoxia (they normally receive 5–15% of pancreatic blood flow despite comprising only 1–2% of organ mass), and their function depends critically on cell-cell communication within the islet microarchitecture. A bioprinted, immunoprotected, vascularized islet construct — if achieved — would represent a functional cure for Type 1 diabetes.

Muscle (skeletal) — Volumetric muscle loss (VML) from trauma, combat injuries, or tumor resection affects hundreds of thousands of patients annually and exceeds the body's natural regenerative capacity, resulting in permanent functional deficit. Current treatment is limited to physical therapy and surgical flap transfer, neither of which restores native muscle function. Bioprinting aims to create aligned, contractile myofiber bundles that can be implanted into the defect to restore force generation. The key challenge is achieving cellular alignment — native skeletal muscle consists of highly organized, parallel fibers that contract in unison. Researchers have used aligned nanofiber scaffolds, electric field stimulation, and directional bioprinting patterns to induce myotube alignment and fusion. Bioprinted muscle constructs have demonstrated measurable contractile force generation and — critically — innervation by host nerve fibers after implantation in animal models, suggesting functional integration is achievable.

Adipose tissue — Soft tissue defects from mastectomy (breast reconstruction), facial trauma, congenital malformations, and lipodystrophy represent a significant reconstructive surgery need. Current options — silicone implants, autologous fat transfer, and dermal fillers — each carry limitations including capsular contracture, reabsorption, and foreign body reactions. Bioprinted adipose constructs offer the possibility of living, vascularized soft tissue implants that integrate permanently with the patient's body. Researchers have fabricated constructs with mature adipocytes that accumulate lipid droplets and secrete adipokines (leptin, adiponectin) over weeks in culture. The clinical challenge is maintaining the construct's soft, compliant mechanical properties while providing enough structural support during the healing period.

Colon and gastrointestinal tissue — Inflammatory bowel disease (IBD, including Crohn's disease and ulcerative colitis) affects approximately 7 million people worldwide, and severe cases require surgical resection of diseased bowel segments — resulting in shortened intestine, malabsorption, and dependence on parenteral nutrition. Bioprinting intestinal tissue aims to fabricate replacement mucosal segments with the crypt-villus organization of native intestinal mucosa — polarized epithelial layers, goblet cells for mucus production, and underlying stromal compartments — that could be implanted to restore absorptive surface area. Researchers have successfully fabricated villus-like architectures that maintain barrier function and nutrient absorption capacity in vitro. The GI tract's constant self-renewal (the intestinal epithelium replaces itself every 3–5 days) makes this a particularly interesting therapeutic target: a bioprinted construct that establishes a functional stem cell niche could, in theory, self-maintain indefinitely after implantation.

Stomach — Gastric tissue loss from cancer resection (gastrectomy), peptic ulcer disease, or caustic injury leaves patients with reduced gastric capacity and severe nutritional consequences including dumping syndrome and malabsorption. Gastric tissue bioprinting is an emerging area focused on fabricating replacement gastric wall segments with the multi-layered architecture — mucosa, submucosa, and muscularis — required for both secretory function and mechanical contraction. The stomach's extreme pH environment (gastric acid, pH 1.5–3.5) and thick mucus barrier add unique engineering challenges. Bioprinted gastric models aim to replicate the gastric pit-gland architecture with mucus-secreting epithelial layers, parietal cells (acid production), and chief cells (enzyme secretion).

Spleen — Splenic tissue bioprinting is the most nascent among the tissues listed here, but it carries therapeutic potential for patients who have undergone splenectomy (surgical removal of the spleen following trauma, cancer, or hematological disorders). Asplenic patients face a lifelong elevated risk of overwhelming post-splenectomy infection (OPSI), a rapidly fatal sepsis caused by encapsulated bacteria. A bioprinted splenic tissue implant that recapitulates the spleen's immune filtration function — red pulp for blood filtration, white pulp for adaptive immune responses, and the marginal zone that captures blood-borne pathogens — could provide immune protection without requiring a full organ transplant. The spleen's highly specialized microarchitecture makes this technically challenging, but the clinical need is clear and the patient population is well-defined.

Across all 15 tissue types, a consistent pattern emerges: the native extracellular matrix of each tissue has a unique composition that directly instructs cell behavior — and the therapeutic success of bioprinted constructs depends on replicating that matrix environment. Skin dECM preserves collagen I/III ratios, elastin, and basement membrane proteins that drive keratinocyte stratification. Cartilage dECM provides the GAG-rich, type II collagen environment that guides chondrogenic differentiation. Bone dECM contains osteoinductive signals including BMP-binding sites and mineralization cues that accelerate MSC commitment to osteogenic lineages. Cardiac dECM preserves myocardial-specific collagens, fibronectin, and laminin that improve cardiomyocyte maturation and sarcomere organization. Liver dECM retains hepatic growth factors like HGF and ECM glycoproteins that maintain hepatocyte polarization and CYP450 metabolic function. Brain dECM is rich in hyaluronic acid, laminin, tenascin, and neural-specific proteoglycans that support neurite outgrowth and synaptogenesis. Vascular dECM provides elastin, collagen IV, and laminin in endothelial-promoting ratios that drive vessel wall maturation. Lung dECM preserves the elastin-rich, mechanically compliant matrix required for alveolar expansion and recoil. Kidney dECM contains nephron-specific basement membrane composition and growth factor gradients that support tubular epithelial organization. Pancreas dECM preserves the islet niche matrix — collagen IV, laminin, and pancreas-specific growth factors — that sustains beta-cell survival and insulin secretion. Muscle dECM provides the myogenic niche with laminin, collagen IV, IGF-1, and HGF that promotes myotube fusion and contractile maturation. Adipose dECM is rich in collagen VI and adipogenic growth factors that drive preadipocyte differentiation. Colon dECM recreates the mucosal-submucosal-muscular signaling gradients that maintain the epithelial stem cell niches characteristic of the GI tract. Stomach dECM supports the specialized parietal and chief cell phenotypes unique to gastric tissue. And spleen dECM provides the reticular fiber network and splenic matrix signals that may enable organization of immune cell niches in bioprinted constructs.

The breadth of tissue types now accessible to bioprinting underscores a central point: the biomaterial must match the biology.  This is why tissue-specific dECM bioinks — like TissueLabs' MatriXpec™ line, available for all 15 tissue types described above in thermal, photocrosslinkable, and ionically crosslinkable formulations — represent a fundamental advance over generic hydrogel approaches. The bioink is not just a carrier; it is an active participant in tissue formation.

What are the biggest challenges in bioprinting today?

Cell expansion — producing enough cells to print with

Before a single filament is deposited, bioprinting faces a bottleneck that is often underestimated: producing enough cells. A single bioprinted tissue construct can require tens of millions to billions of cells, depending on the tissue type and construct size. A clinically relevant cardiac patch may need over one billion cardiomyocytes. A bioprinted liver segment requires hundreds of millions of hepatocytes. Even a modest cartilage disc demands tens of millions of chondrocytes. These numbers far exceed what a standard tissue culture flask can produce in a reasonable timeframe.

The challenge varies dramatically by cell type. Primary cells harvested from patient biopsies (hepatocytes, chondrocytes, keratinocytes) have limited proliferative capacity — they senesce after a finite number of divisions and often lose their functional phenotype during expansion (hepatocytes lose CYP450 activity, chondrocytes dedifferentiate toward a fibroblastic phenotype). Immortalized cell lines proliferate indefinitely but do not represent normal tissue biology. iPSC-derived cells (cardiomyocytes, neurons, beta cells) offer a theoretically unlimited source, but differentiation protocols are expensive, time-consuming (typically 2–6 weeks per batch), and yield variable purity — undifferentiated iPSCs remaining in the population pose a tumorigenic risk in therapeutic applications.

Scaling cell production to bioprinting volumes requires bioreactor systems (stirred-tank, hollow-fiber, or rocking-platform) that can expand cells in three-dimensional suspension culture while maintaining phenotype — an entire field of bioprocess engineering in its own right, and a significant cost and timeline component of any bioprinting workflow. The biomaterial environment during expansion also matters: cells expanded on standard tissue culture plastic in 2D often behave differently than cells maintained in 3D throughout the process. There is growing evidence that expanding cells in tissue-matched ECM environments better preserves their functional phenotype during the weeks of culture required to reach bioprinting-scale numbers.

Cell viability during printing

Cell viability is the most fundamental constraint in bioprinting — every parameter choice, from printing modality to bioink formulation to crosslinking chemistry, must be evaluated against the question: will the cells survive the process? The sources of cell damage differ between extrusion and light-based bioprinting, and understanding both is essential for designing workflows that preserve biological function.

In extrusion bioprinting, the primary threat is mechanical shear stress. Pushing cells through a narrow nozzle subjects them to hydrodynamic forces that can rupture cell membranes, damage cytoskeletal structures, and trigger apoptosis. As reviewed by Xu and colleagues in Military Medical Research (2022), cell viability in cylindrical nozzles can be ten times lower than in conical (tapered) nozzles, and dispensing pressure is the dominant factor causing cell damage. Blaeser and colleagues quantified the threshold in Advanced Healthcare Materials (2016): shear stress must stay below approximately 5 kPa to maintain greater than 90% viability, and both viability and proliferative capacity decline sharply above that level. This is where the dispensing mechanism matters most. In pneumatic systems, the operator sets an air pressure, and the resulting shear depends on bioink viscosity, temperature, and rheological behavior — all of which vary between formulations and batches — making it difficult to predict and control the forces cells experience. Volumetric (piston-driven) systems address this fundamentally by controlling the volume of bioink displaced per motor step rather than the pressure applied. The flow rate is determined by the plunger's physical displacement, not by the bioink's properties, enabling precise deposition that keeps shear within the safe zone without trial-and-error pressure calibration.

In light-based bioprinting, shear stress is largely absent — cells are suspended in a liquid bioresin that is cured in place, with no nozzle passage. Instead, the primary viability concerns are photoinitiator toxicity and UV/near-UV radiation damage. Photopolymerization requires a photoinitiator molecule that generates free radicals upon light exposure; these radicals crosslink the bioresin but can also damage cell membranes, DNA, and intracellular proteins if their concentration is too high or exposure time too long. Common photoinitiators like Irgacure 2959 (activated at 365 nm) have documented cytotoxic effects at concentrations above 0.05–0.1% w/v, while newer alternatives like LAP (lithium phenyl-2,4,6-trimethylbenzoylphosphinate) offer higher water solubility, activation at visible wavelengths (405 nm), and lower cytotoxicity at equivalent concentrations. The choice of wavelength is equally important: shorter UV wavelengths (365 nm) carry more energy per photon and greater potential for DNA damage than visible-light wavelengths (405, 450, 530 nm), particularly during extended exposures. MSLA systems offer an advantage here because each layer is cured in a single brief flash (typically seconds) rather than traced point by point, minimizing total radiation exposure time.

Across both modalities, bioink formulation plays a protective role. Higher-viscosity bioinks shield cells from shear during extrusion by distributing forces more evenly across the filament cross-section. In light-based systems, bioresins with antioxidant additives or radical-scavenging components can reduce collateral free radical damage to cells. And in both cases, the biofabrication window applies: the processing conditions that produce the best structural fidelity are often the harshest on cells, and finding the right compromise — or using advanced crosslinking strategies that decouple printability from viability — remains one of bioprinting's core ongoing challenges.

Vascularization

Creating functional blood vessel networks within bioprinted constructs remains one of the field's grand challenges. The constraint is biological: without a blood supply, cells in the interior of constructs thicker than approximately 200 µm die from oxygen and nutrient deprivation. Every tissue thicker than a few cell layers in the human body is permeated by capillary networks spaced no more than 200 µm apart. Replicating this density in a bioprinted construct — across multiple size scales from large-diameter arteries down to capillaries smaller than 100 µm — is an engineering problem that no current technology has fully solved.

Current approaches attack the problem from multiple directions. Sacrificial ink printing deposits a temporary material (typically Pluronic F-127 or gelatin) within a permanent bioink matrix; after printing, the sacrificial material is dissolved or melted away, leaving behind hollow, perfusable channels. Coaxial bioprinting creates core-shell tubular structures in a single pass — an inner sacrificial core surrounded by a cell-laden outer wall — enabling direct fabrication of vessel-like tubes with controlled wall thickness and diameter. Angiogenic factor loading embeds VEGF, FGF, or other growth factors into the bioink matrix to stimulate sprouting angiogenesis from host vasculature after implantation. And pre-vascularization strategies co-culture endothelial cells within the construct before implantation, allowing microvascular network self-assembly in vitro.

Reproducibility and standardization

When bioprinting moves from academic publications to clinical products and regulatory-grade pharmaceutical tools, constructs must be reproducible — not just within a single lab, but across institutions, operators, and time. The 2024 multi-laboratory round robin study by Garces and colleagues — the first of its kind in the field — sent identical bioink formulations and print files to 12 sites across Germany. The results exposed a critical reality: without standardized calibration workflows and automated dispensing, extrusion bioprinting results vary significantly between operators and even between prints by the same operator. Sources of variability included inconsistent nozzle-to-substrate calibration, operator-dependent pressure tuning, environmental temperature differences, and bioink preparation protocols that were nominally identical but practically divergent.

This is not just an academic concern — it has direct implications for regulatory acceptance. The FDA and EMA require manufacturing process consistency for any therapeutic product, and pharmaceutical companies using bioprinted tissue models for drug screening need assurance that a model fabricated on Monday produces the same biological readout as one fabricated on Friday. Volumetric extrusion systems help address this by replacing pressure-dependent, operator-tuned dispensing with motor-step-controlled, volume-defined deposition. The fixed relationship between motor input and bioink output removes the most significant source of variability — the air-pressure-to-flow-rate relationship that changes with every bioink formulation, temperature shift, and batch variation. Complementary standardization efforts — including standardized bioink characterization protocols, automated print quality assessment, and open-access parameter databases — are equally important and represent content areas where the bioprinting community needs shared resources.

Regulatory considerations

Bioprinted products occupy an unusual and still-evolving regulatory space that spans multiple existing frameworks without fitting neatly into any of them. A bioprinted tissue construct intended for implantation contains living cells (biological product), a biomaterial scaffold (medical device), and potentially bioactive molecules (drug) — making it a combination product that must navigate overlapping regulatory jurisdictions. O'Connell and colleagues reviewed the challenge in Regenerative Medicine (2023), noting that bioprinted products fall under "combination product" frameworks in both the EU (Advanced Therapy Medicinal Products / ATMPs regulated by the EMA's Committee for Advanced Therapies) and the FDA (where they may qualify for Regenerative Medicine Advanced Therapy / RMAT designation, providing expedited review pathways).

The regulatory landscape is moving, but slowly. The world's first human clinical trial of a 3D bioprinted product commenced in 2022, marking a pivotal milestone. However, the FDA's CBER has not yet approved any 3D-printed biological products, and fundamental questions remain unresolved: how to characterize batch-to-batch consistency of living constructs, how to define shelf life for products that are biologically active and changing, how to validate sterility without destroying the product, and how to establish potency assays for constructs whose therapeutic function depends on complex multicellular behavior rather than a single measurable molecule.

For bioprinted NAMs used in drug development (rather than implantation), the regulatory path is clearer — the FDA Modernization Act 2.0 and EMA NAM initiatives have explicitly endorsed these tools — but standardization and validation benchmarks are still being established. For now, all TissueLabs products are for research use only — a transparent compliance position that reflects where the field currently stands and avoids premature clinical claims while the regulatory frameworks mature.

How do you get started with bioprinting?

If you are setting up a bioprinting capability in your lab for the first time, here is a practical framework:

Step 1: Define your application. What tissue or model are you trying to create? This determines your modality (extrusion vs. light-based), your bioink requirements, and the resolution you need.

Step 2: Choose your modality. For most labs, volumetric extrusion bioprinting is the best starting point — it handles the widest range of bioinks, offers the best reproducibility through direct volume control, and supports the broadest set of tissue engineering applications. Add MSLA capability if your work requires micron-level precision for microfluidics or organ-on-chip applications.

Step 3: Select your bioink — and match it to your biology. Start with established formulations where published protocols exist. Alginate and GelMA are widely used starting points for learning a system. But when your application demands physiologically relevant results, transition to tissue-specific dECM bioinks. The difference between culturing cells in a generic hydrogel and in their native tissue-matched matrix shows up in gene expression, differentiation, drug response, and every downstream functional readout.

Step 4: Start simple, then scale. Print single-material constructs first to learn your system's behavior. Then add complexity: multi-material printing, coaxial structures, gradient tissues.

Step 5: Invest in training. Bioprinting has a learning curve. Formal training courses — like the TissueLabs' online courses or our Seasonal Schools on Advanced Bioprinting — compress the time from unboxing to first reproducible tissue model.

References

All scientific claims in this guide are supported by peer-reviewed literature. Key references cited above:

1. Murphy SV, Atala A. "3D bioprinting of tissues and organs." Nature Biotechnology, 2014; 32(8):773–785.

2. Moroni L, Boland T, Burdick JA, De Maria C, Derby B, Forgacs G, Groll J, et al. "Biofabrication: A Guide to Technology and Terminology." Trends in Biotechnology, 2018; 36(4):384–402.

3. Malda J, Visser J, Melchels FP, Jüngst T, Hennink WE, Dhert WJA, Groll J, Hutmacher DW. "25th Anniversary Article: Engineering Hydrogels for Biofabrication." Advanced Materials, 2013; 25(36):5011–5028.

4. Levato R, Jungst T, Scheuring RG, Blunk T, Groll J, Malda J. "From Shape to Function: The Next Step in Bioprinting." Advanced Materials, 2020; 32(12):1906423.

5. Zhang YS, Haghiashtiani G, Hübscher T, et al. "3D extrusion bioprinting." Nature Reviews Methods Primers, 2021; 1(1):75.

6. Blaeser A, Duarte Campos DF, Puster U, Richtering W, Stevens MM, Fischer H. "Controlling Shear Stress in 3D Bioprinting is a Key Factor to Balance Printing Resolution and Stem Cell Integrity." Advanced Healthcare Materials, 2016; 5(3):326–333.

7. Li M, Tian X, Zhu N, Schreyer DJ, Chen X. "Modeling process-induced cell damage in the biodispensing process." Tissue Engineering Part C: Methods, 2010; 16(3):533–542.

8. Ning L, Yang B, Mohabatpour F, Betancourt N, Sarker MD, Papagerakis P, Chen X. "Process-induced cell damage: pneumatic versus screw-driven bioprinting." Biofabrication, 2020; 12(2):025011.

9. Garces DG, Strauss S, Gretzinger S, et al. "On the reproducibility of extrusion-based bioprinting: round robin study on standardization in the field." Biofabrication, 2024; 16(1):015002.

10. Levato R, Lim KS, Li W, Flores-Bustos AU, et al. "Light-based vat-polymerization bioprinting." Nature Reviews Methods Primers, 2023.

11. Li W, Wang M, Ma H, Chapa-Villarreal FA, Lobo AO, Zhang YS. "Stereolithography apparatus and digital light processing-based 3D bioprinting for tissue fabrication." iScience, 2023; 26(2):106039.

12. Bhusal A, Miri AK, et al. "Digital Light Processing Bioprinting Advances for Microtissue Models." ACS Biomaterials Science & Engineering, 2022; 8(4):1381–1395.

13. Bernal PN, Delrot P, Loterie D, Li Y, Malda J, Moser C, Levato R. "Volumetric Bioprinting of Complex Living-Tissue Constructs within Seconds." Advanced Materials, 2019; 31(42):1904209.

14. Jing S, Lian L, Hou Y, Li Z, et al. "Advances in volumetric bioprinting." Biofabrication, 2024; 16(1):012004.

15. Gudapati H, Dey M, Ozbolat I. "A comprehensive review on droplet-based bioprinting: Past, present and future." Biomaterials, 2016; 102:20–42.

16. Gupta D, Derman ID, Xu C, Huang Y, Ozbolat IT. "Droplet-based bioprinting." Nature Reviews Methods Primers, 2025; 5(1):25.

17. Dou C, Perez V, Qu J, Tsin A, Xu B, Li J. "A State-of-the-Art Review of Laser-Assisted Bioprinting and its Future Research Trends." ChemBioEng Reviews, 2021; 8(5):517–534.

18. Yusupov V, Churbanov S, Churbanova E, et al. "LIFT-bioprinting, is it worth it?" Bioprinting, 2019; 15:e00052.

19. Samandari M, Mostafavi A, Quint J, Memić A, Tamayol A. "In situ bioprinting: intraoperative implementation of regenerative medicine." Trends in Biotechnology, 2022; 40(10):1229–1247.

20. Groll J, Burdick JA, Cho D-W, Derby B, Gelinsky M, Heilshorn SC, Jüngst T, Malda J, et al. "A definition of bioinks and their distinction from biomaterial inks." Biofabrication, 2019; 11(1):013001.

21. Gungor-Ozkerim PS, Inci I, Zhang YS, Khademhosseini A, Dokmeci MR. "Bioinks for 3D bioprinting: an overview." Biomaterials Science, 2018; 6(5):915–946.

22. Yue K, Trujillo-de Santiago G, Alvarez MM, Tamayol A, Annabi N, Khademhosseini A. "Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels." Biomaterials, 2015; 73:254–271.

23. Gonzalez-Fernandez T, Tenorio AJ, Campbell KT, Silva EA, Leach JK. "Alginate-Based Bioinks for 3D Bioprinting and Fabrication of Anatomically Accurate Bone Grafts." Tissue Engineering Part A, 2021; 27(17–18):1168–1181.

24. Antich C, de Vicente J, Jiménez G, et al. "Bio-inspired hydrogel composed of hyaluronic acid and alginate as a potential bioink for 3D bioprinting of articular cartilage engineering constructs." Acta Biomaterialia, 2020; 106:114–123.

25. Pati F, Jang J, Ha D-H, Won Kim S, Rhie JW, Shim JH, Kim DH, Cho D-W. "Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink." Nature Communications, 2014; 5:3935.

26. Kim BS, Das S, Jang J, Cho D-W. "Decellularized Extracellular Matrix-based Bioinks for Engineering Tissue- and Organ-specific Microenvironments." Chemical Reviews, 2020; 120(19):10608–10661.

27. Xu HQ, Liu JC, Zhang ZY, Xu CX. "A review on cell damage, viability, and functionality during 3D bioprinting." Military Medical Research, 2022; 9(1):70.

28. Daly AC, Critchley SE, Rencsok EM, Kelly DJ. "A comparison of different bioinks for 3D bioprinting of fibrocartilage and hyaline cartilage." Biofabrication, 2016; 8(4):045002.

29. Yan Y, Li X, Gao Y, et al. "3D bioprinting of human neural tissues with functional connectivity." Cell Stem Cell, 2024; 31(2):260–274.

30. O'Connell CD, Dalton PD, O'Connell GG, Wallace GG. "The Regulatory Challenge of 3D Bioprinting." Regenerative Medicine, 2023; 18(8):659–674.